To quantify the hepatic safety of pazopanib and comparator anti-vascular endothelial growth factor (VEGF) therapies in clinical practice among renal cell carcinoma (RCC) patients. The gene discussed is VEGFA; the disease is hereditary clear cell renal cell carcinoma.